Topic:

R&D

Latest Headlines

Latest Headlines

Struggling Teva slashing R&D, chops 14 programs as it retreats on two fronts

Troubled Teva is circling its research wagons around CNS and respiratory diseases, carving out more than $500 million in research costs over the next three years with plans to shelve or spin out 14 clinical programs as it retreats from women's health and oncology.

Accelovance poaches a Big Pharma vet to lead its oncology efforts

Early-phase CRO Accelovance has landed a former Pfizer and Otsuka exec to flesh out its efforts in oncology, part of a sweeping growth strategy that has seen the company expand across the U.S.

Facebook mulls move into healthcare sector

Reuters reports that Facebook is considering setting up patient support communities and has met with people in the medical industry to discuss its plans.

Hopkins physician creates 3-D printed hands for pediatric patients

As the med tech industry addresses a growing need for devices geared toward children, a Baltimore, MA-based physician is creating 3-D printed hands developed specifically for pediatric patients.

Illumina teams with AB Sciex to add proteomics apps to BaseSpace

Illumina has teamed up with AB Sciex to add proteomic data analysis capabilities to its BaseSpace platform. As a result of the collaboration, Illumina is hosting four apps for processing, analyzing and visualizing proteomics mass spectrometry data on BaseSpace.

NIH grants up to $70M to develop vaccine adjuvants

The National Institutes of Health has forged 7 research agreements with academic and industry partners aimed at identifying new adjuvant candidates that could be used in vaccines to boost immune responses against various pathogens.

Feds rally behind Mapp as Ebola spreads, but production remains a challenge

A novel treatment made by tiny Mapp Biopharmaceutical may be the key to beating back West Africa's Ebola outbreak, but despite the support of the U.S. government and some of the world's largest charities, producing enough to counter the spread will be difficult.

Eliquis bleeding antidote aces PhIII study, threatening to beat rivals to market

On Wednesday, Pfizer and Bristol-Myers Squibb got some positive data on an undo med for their market trailer, Eliquis. And that antidote could be on the way in the not-too-distant future.

Projection: Implantable drug delivery market to reach $21.1B by 2018

Transparency Market Research predicts that the worldwide implantable drug delivery market will reach $21.1 billion by 2018.

Needle-coated pill offers safe oral delivery of insulin, vaccines

A pill coated with tiny needles may help improve oral treatments, according to researchers. When swallowed, the pill delivers large molecules such as insulin into the lining of the stomach and does so more efficiently than an injection under the skin.